TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00204425

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: exercise/soy isoflavone
Description: Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: exercise/soy isoflavone
Description: Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: exercise/soy isoflavone
Description: Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
Study: NCT00204425

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: exercise/soy isoflavone
Description: Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
Study: NCT03164616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + cisplatin
Description: Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
Study: NCT01765517

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Administration of probiotics daily for 26 weeks and compared to placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo daily for 26 weeks and compared to probiotics group
Study: NCT04028154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane (ESP) Block
Description: ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
Study: NCT02781363

Intervention type: OTHER
Group type: OTHER
Intervention: Thoracic ultrasound
Study: NCT04028154

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracolumbar interfacial plane (TLIP) Block
Description: TLIP Block: BilateralTLIP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
Study: NCT02864004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine
Description: Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies
Study: NCT02781363

Intervention type: OTHER
Group type: OTHER
Intervention: Thoracic ultrasound

Intervention type: OTHER
Group type: OTHER
Intervention: CXR

Intervention type: OTHER
Group type: OTHER
Intervention: CXR
Study: NCT00922857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation
Description: The training begins 5 days after the initial assessment. It consists of 3 weekly sessions for 8 consecutive weeks, including the following activities interspersed with periods of rest, according to the needs of patients
Study: NCT01280331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003 (morphine sulfate and oxycodone hydrochloride)
Description: Two Q8003 6 mg/4 mg IR Capsules q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulfate
Description: Two morphine sulfate 12 mg IR capsules q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCl
Description: Two oxycodone HCl 8 mg IR Capsules q6h
Study: NCT04017234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: frequency following response, eye exercise, and transcutaneous
Description: frequency following response, eye exercise, and TENS for 3 times per week during 4 weeks
Study: NCT03904160

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Weight management
Description: Please see the arm descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight management
Description: Please see the arm descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight management
Description: Please see the arm descriptions.
Study: NCT03489694

Intervention type: PROCEDURE
Intervention: Skin test endpoint titration
Description: An allergen that is suitable to cause skin reactions when introduced to the forearm through pricking will be administered in doubling concentrations.
Study: NCT03722810

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: The intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. These chronic diseases are the four conditions at the top of a list of diseases with high disability-adjusted life years (DALY) scores in Switzerland: ischaemic heart disease, low back pain, major depressive disorder and COPD.~GP teachers and students will be told that the students' intervention interviews need to be unaccompanied and at patients' own homes. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: In the sham comparator, the student's allocated GP teacher will be give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher. The document is designed to have real educational value, and to complement BIHAM's department-based consultation skills teaching.
Study: NCT01332656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombrabulin (AVE8062)
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form:solution~Route of administration: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study: NCT01405430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab + blood samples
Description: Bevacizumab will be administered according to investigators appreciation.~Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab.
Study: NCT02013830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
Study: NCT03840499

Intervention type: DRUG
Intervention: Optimal medical therapy
Description: Optimal medical therapy

Intervention type: DRUG
Intervention: Optimal medical therapy
Description: Optimal medical therapy
Study: NCT02322788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline sulphate
Description: Bricanyl Turbuhaler M2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbutaline sulphate
Description: Bricanyl Turbuhaler M3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for terbutaline sulphate
Description: Placebo Turbuhaler M2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for terbutaline sulphate
Description: Placebo Turbuhaler M3
Study: NCT03170388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-126 Gel
Description: Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-126 Component A
Description: Component A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-126 Component B
Description: Component B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-126 Component C
Description: Component C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-126 Vehicle Gel
Description: Vehicle Gel
Study: NCT02497794

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chew gum
Description: The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chew gum
Description: The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
Study: NCT03328728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Matrix / A-CP HA Kit
Description: Treatment with a single intra-articular injection in the knee of Cellular Matrix / A-CP HA Kit; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One
Description: Treatment with a single intra-articular injection in the knee of Synvisc-One; Synvisc-One (hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing hylans. Hylans are derivatives of hyaluronans (sodium salt of hyaluronic acid). Hylan A has an average molecular weight of 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains hylan A and hylan B (8.0 mg per ml) in buffered physiological sodium chloride solution.
Study: NCT00970255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lingual Frenulum frenotomy
Description: Clipping the lingual frenulum with scissors

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham frenotomy
Description: Sham Clipping the lingual frenulum with scissors
Study: NCT01317784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid tests for HIV, HCV, HBV, and syphilis
Description: Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIV/HCV
Description: Choice of 10 different tests for HIV and hepatitis C.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIV/syphilis
Description: Choice of 7 different tests for HIV and syphilis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIV only
Description: Choice of 4 different tests for HIV only.
Study: NCT04403763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241622
Description: Topical eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241622
Description: Topical eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241622
Description: Topical eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241622
Description: Topical eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241622
Description: Topical eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241622
Description: Topical eye drop

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical eye drop
Study: NCT00920257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2141795
Description: GSK2141795 is an oral AKT inhibitor.
Study: NCT03981042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: After the anesthetic induction with sufentanil, propofol and atracurium, patients will be ventilated with mask until:~- Monitoring group: TOF ratio at the corrugator supercilli will be measured every 15 s after injection of atracurium. When TOF ratio reach 0, laryngoscopy with intubation will be performed
Study: NCT01064817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRM-151
Description: PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
Study: NCT01045707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Injected s.c. (under the skin) once daily. Dose was individually adjusted.
Study: NCT00918918

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcohol + orange juice
Description: 100 mL Vodka (37.5 vol%; 30 gram of alcohol/day) + 200 mL orange juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orange juice
Description: 200 mL orange juice
Study: NCT03416491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-136
Description: KW-136 30 mg was provided in 3 capsules, 10 mg each, and KW-136 60 mg in a single capsule of 60 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-136
Description: KW-136 30 mg was provided in 3 capsules, 10 mg each, and KW-136 60 mg in a single capsule of 60 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-136
Description: KW-136 30 mg was provided in 3 capsules, 10 mg each, and KW-136 60 mg in a single capsule of 60 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir was provided in a single tablet of 400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir was provided in a single tablet of 400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir was provided in a single tablet of 400 mg.
Study: NCT01139749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral isotretinoin
Description: capsules of 20 mg a day, every other day, for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salicylic acid and ciclopirox olamine
Description: Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months
Study: NCT02588547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: IV granisetron 1 mg before spinal anethesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: IV granisetron 0.7 mg before spinal anethesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: IV 2 ml 0.9 sodium chloride before spinal anethesia
Study: NCT04216420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MERM-observed self-administered therapy
Description: The MERM device has an electronic module and a medication container that records adherence, stores medication, emits audible and visual on-board alarms to remind patients to take their medications on time and refill, and enables providers to download the data and monitor adherence. It is manufactured by Wisepill Technologies, South Africa.
Study: NCT03226119

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MP Diagnostics HTLV Blot 2.4
Description: HTLV I/II Confirmation and Differentiation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MP Diagnostics HTLV Blot 2.4
Description: HTLV I/II Confirmation and Differentiation
Study: NCT03271606

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS
Description: The investigators mainly used enhanced measures perioperatively in mediastinal surgery as these used in other surgery

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Traditional measures
Description: The investigators mainly used traditional measures perioperatively in mediastinal surgery as these used in other surgery
Study: NCT00111358

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Study: NCT01438086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mecasermin
Description: Intracoronary bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mecasermin
Description: Intracoronary bolus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride injection
Description: Intracoronary bolus
Study: NCT02105064

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM rTMS
Description: Sham rTMS, without brain stimulation
Study: NCT04807322

Intervention type: PROCEDURE
Intervention: Reverse Total Shoulder Arthroplasty (RTSA)
Description: Implantation of a Reverse Total Shoulder Arthroplasty

Intervention type: PROCEDURE
Intervention: Reverse Total Shoulder Arthroplasty (RTSA)
Description: Implantation of a Reverse Total Shoulder Arthroplasty
Study: NCT01980121

Intervention type: DEVICE
Intervention: Ultrasound
Description: Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
Study: NCT03973684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pdt experimental group
Description: G1-40 patients Photodynamic therapy with methylene blue as photosensitizer~device irradiation with low intensity laser (wave length = 660 nm) 9J (Jaules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pdt experimental group
Description: G1-40 patients Photodynamic therapy with methylene blue as photosensitizer~device irradiation with low intensity laser (wave length = 660 nm) 9J (Jaules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated.
Study: NCT01272427

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with glucose
Description: 0.75 g/kg body weight of glucose added to water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with glucose
Description: 0.75 g/kg body weight of glucose added to water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water and whey protein
Description: 0.75 g/kg body weight of whey protein added to water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water and whey protein
Description: 0.75 g/kg body weight of whey protein added to water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with noncaloric sweetener
Description: 0.15 g of sucralose added to water
Study: NCT01909258

Intervention type: OTHER
Intervention: Goniometric measure of pelvic extension reserve.
Description: The pelvic extension reserve (°) is measured via goniometry.~The goniometric measurements will be taken once by an investigator on all subjects and once by a different investigator on half of the subjects (with balanced distribution of morphotypes).

Intervention type: OTHER
Intervention: Photographic measure of pelvic extension reserve.
Description: The pelvic extension reserve (°) is measured using photography.~Photographic measurements will be performed twice one investigator and 1 time by a different investigator (total of three measurements).

Intervention type: OTHER
Intervention: EOS measure of pelvic extension reserve.
Description: The pelvic extension reserve (°) is measured using the imaging system EOS.~Five X-rays will be made for each volunteer on the EOS system. The first is a frontal shot in a bipedal position, reference snapshot for verifying the absence of spinal deformity or hip pathology. The second and third are profile shots, one on the left and one on the right, whole body, bipedal position; serving as a reference picture. The fourth is profile shot, whole body, with the left hip in hyperextension. For maximum left hip hyperextension, the right leg rests on a step of varying height, and the hip is maximally flexed. The fifth is a profile shot, full body, with the right hip in hyperextension. For a maximum right hip hyperextension, the left leg rests on a step of varying height, and the hip is maximally flexed.
Study: NCT00675246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)